{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:42:40Z","timestamp":1768466560027,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.clinthera.2009.09.008","type":"journal-article","created":{"date-parts":[[2009,10,19]],"date-time":"2009-10-19T04:03:24Z","timestamp":1255925004000},"page":"1966-1976","source":"Crossref","is-referenced-by-count":36,"title":["Effect of agalsidase alfa replacement therapy on fabry disease\u2014related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Christoph","family":"Kampmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.09.008_bib1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.09.008_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.09.008_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet."},{"key":"10.1016\/j.clinthera.2009.09.008_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet."},{"key":"10.1016\/j.clinthera.2009.09.008_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J."},{"key":"10.1016\/j.clinthera.2009.09.008_bib6_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08035320510028058","article-title":"Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy","volume":"94","author":"Shah","year":"2005","journal-title":"Acta Paediatr Suppl."},{"key":"10.1016\/j.clinthera.2009.09.008_bib6_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08035320510028058","article-title":"Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy","volume":"94","author":"Shah","year":"2005","journal-title":"Acta Paediatr Suppl."},{"key":"10.1016\/j.clinthera.2009.09.008_bib7","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy [published online ahead of print February 9, 2009]. Nephrol Dial Transplant."},{"key":"10.1016\/j.clinthera.2009.09.008_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00392-002-0848-5","article-title":"The heart in Anderson Fabry disease","volume":"91","author":"Kampmann","year":"2002","journal-title":"Z Kardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib9","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1161\/CIRCULATIONAHA.105.584292","article-title":"Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease","volume":"113","author":"Hasegawa","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2009.09.008_bib10","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.0000062036.35852.01","article-title":"Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: Comparison with biopsy findings","volume":"107","author":"Funabashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2009.09.008_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J."},{"key":"10.1016\/j.clinthera.2009.09.008_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0735-1097(86)80238-8","article-title":"Echocardiographic abnormalities and disease severity in Fabry's disease","volume":"7","author":"Goldman","year":"1986","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib13","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/hrt.2006.113886","article-title":"Treatment of Anderson-Fabry disease","volume":"94","author":"Linhart","year":"2008","journal-title":"Heart."},{"key":"10.1016\/j.clinthera.2009.09.008_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/hrt.2004.035584","article-title":"The natural history of left ventricular systolic function in Anderson-Fabry disease","volume":"91","author":"Shah","year":"2005","journal-title":"Heart."},{"key":"10.1016\/j.clinthera.2009.09.008_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0002-9149(94)90106-6","article-title":"Electrophysiologic findings in Fabry's disease with a short PR interval","volume":"74","author":"Pochis","year":"1994","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.09.008_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2009.09.008_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2009.09.008_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.clinthera.2009.09.008_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renalstabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebocontrolled clinical trial of agalsidasealfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart."},{"key":"10.1016\/j.clinthera.2009.09.008_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics."},{"key":"10.1016\/j.clinthera.2009.09.008_bib26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2009.09.008_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet."},{"key":"10.1016\/j.clinthera.2009.09.008_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2009.09.008_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2005.03.016","article-title":"Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement","volume":"46","author":"Pisani","year":"2005","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.clinthera.2009.09.008_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart."},{"key":"10.1016\/j.clinthera.2009.09.008_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis."},{"key":"10.1016\/j.clinthera.2009.09.008_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet Med."},{"key":"10.1016\/j.clinthera.2009.09.008_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.clinthera.2009.09.008_bib34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: Overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.clinthera.2009.09.008_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.CIR.58.6.1072","article-title":"Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements","volume":"58","author":"Sahn","year":"1978","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2009.09.008_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.clinthera.2009.09.008_bib37","doi-asserted-by":"crossref","first-page":"II19","DOI":"10.1161\/01.HYP.9.2_Pt_2.II19","article-title":"Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods","volume":"9","author":"Devereux","year":"1987","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2009.09.008_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0735-1097(92)90385-Z","article-title":"Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight","volume":"20","author":"de Simone","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib39","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinthera.2009.09.008_bib40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.clinthera.2009.09.008_bib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.hlc.2007.03.007","article-title":"Cardiovascular manifestations in Fabry disease: A clinical and echocardiographic study","volume":"16","author":"Sadick","year":"2007","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.clinthera.2009.09.008_bib44","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00296520","article-title":"A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier","volume":"90","author":"Uchino","year":"1995","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.clinthera.2009.09.008_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","article-title":"Endothelial markers and homocysteine in patients with classic Fabry disease","volume":"91","author":"Demuth","year":"2002","journal-title":"Acta Paediatr Suppl."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:10:49Z","timestamp":1558581049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0149291809003373"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.09.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}